T-cell lymphoma Program in Pharmaceutical Benefits Scheme (PBS) 012-18051112
Expand allT-cell Lymphoma restriction and item codes
Do not share this attachment externally. See Freedom of Information - Information Publication Scheme.
PBS CTCL and PTCL restriction and item codes
FAQs from Service Officers
Table 1: see Table 2 in Processing Complex Authority Required Listings for FAQs about all Complex programs.
|
Item |
Description |
|
1 |
How is the quantity of brentuximab and mogamulizumab entered in OPA? The quantity must be entered in OPA as the required dose in milligrams (mg). See Recording dose and frequency in online pbs authorities system for more details. |
|
2 |
If a dose change for brentuximab or mogamulizumab is required, does the prescriber need to obtain a new approval? Yes. Any dose change of greater than 10%, whether an increase or a decrease, requires a new approval. Any replacement for a dose change must be entered under the same item and restriction code as the previous approval, and the relevant rejection should be overridden with the comment 'dose change'. |